Welcome to our dedicated page for GRVI news (Ticker: GRVI), a resource for investors and traders seeking the latest updates and insights on GRVI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GRVI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GRVI's position in the market.
Grove (NASDAQ: GRVI) announced a partnership with Alfi to launch its largest advertising campaign, utilizing Alfi's AI-driven platform on digital tablets in Uber and Lyft rideshares across 12 major markets. This initiative aims to enhance audience targeting and engagement while maximizing ROI. Grove, a leader in the CBD and hemp wellness sector, emphasizes the importance of technology in overcoming advertising restrictions typically faced in the industry. CEO Allan Marshall expressed hope for this partnership to grow nationally and reshape advertising within the sector.
Alfi has partnered with Grove to launch a digital out-of-home (DOOH) advertising campaign across 12 major markets, utilizing Alfi's platform to increase the efficiency and targeting capability of ads for Grove’s CBD products.
This collaboration aims to enhance brand awareness and is anticipated to develop into a multi-million-dollar opportunity. The partnership highlights the increasing relevance of programmatic DOOH advertising, which is projected to grow significantly in the coming years.
Grove Inc. (NASDAQ: GRVI) has successfully acquired VitaMedica, a leader in online supplements for health and recovery, enhancing its position in the nutraceutical market. This acquisition is expected to be accretive, positively impacting both top line and net income. VitaMedica boasts over $10 million in sales and has served over 1 million patients, supported by numerous physician recommendations. Grove aims to leverage VitaMedica's established product line and clinical expertise to expand its health and wellness portfolio and drive future growth.
Grove, Inc. (NASDAQ:GRVI) reported preliminary fourth quarter fiscal 2021 revenues between $10.1 million and $10.4 million, marking a growth of over 300% year-over-year. The company achieved a net income of $1.5 million to $2 million, a turnaround from a loss of over $700,000 in the same quarter of the previous year. For the full fiscal year, revenues increased to $23.6 million - $23.9 million from $7.4 million in 2020, with net income of $2 million - $2.5 million compared to a loss of over $5 million.
Full financial results will be released on or before September 15, 2021.
Grove, Inc. (NASDAQ:GRVI) has announced the launch of its new plant-based gummy vitamin product line, Qubes, designed to capitalize on the growing demand in the vitamin market. The product range includes unique offerings such as Apple Cider Vinegar + Acai and Turmeric Immunity, with an upcoming Algae Oil supplement as an alternative to fish oil. The global gummy vitamins market is projected to grow from USD 5.9 billion in 2020 to USD 10.6 billion by 2025 at a CAGR of 12.5%. CEO Allan Marshall emphasizes the company’s strategic expansion into multiple profitable markets.
Grove Inc. (NASDAQ: GRVI) announces a non-binding letter of intent to acquire Vitamedica, a prominent online seller of health supplements, aiming to enter the nutraceutical market. The acquisition could enhance Grove's operations, combining its innovative manufacturing with Vitamedica’s extensive product line, which has been endorsed by over 1 million patients. The deal may also strengthen Grove's position in the growing vitamin-gummy market, projected to reach USD 10.6 billion by 2025. However, the agreement is contingent on successful negotiations and due diligence.
Grove, Inc. (NASDAQ:GRVI) has announced the pricing of its initial public offering (IPO) of 2,200,000 shares at $5.00 per share, aiming for approximately $11.0 million in gross proceeds. The company has also granted underwriters a 45-day option for an additional 330,000 shares. The IPO is set to close around June 28, 2021, pending customary conditions. Trading on the Nasdaq Capital Market is anticipated to start on June 24, 2021. Grove specializes in products made from industrial hemp and CBD, targeting various markets including beauty and food sectors.